^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Keytruda (pembrolizumab)

    i
    Other names: MK-3475, SCH 900475, 1374853-91-4, ORG 307488, SCH-900475, SCH900475, ORG 307488-0, MK 3475, MK3475
    Company:
    Merck (MSD)
    Drug class:
    PD1 inhibitor
    Related drugs:
    23h
    KEYNOTE A99: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (clinicaltrials.gov)
    P1/2, N=296, Active, not recruiting, Inhibrx Biosciences, Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)
    |
    EGFR mutation • TMB-H • MSI-H/dMMR • ALK rearrangement
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • ordastobart (INBRX-106)
    1d
    A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101) (clinicaltrials.gov)
    P1, N=590, Recruiting, GlaxoSmithKline | N=316 --> 590
    Enrollment change • Pan tumor
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • risvutatug rezetecan (GSK5764227)
    1d
    KEYNOTE-C62: Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers (clinicaltrials.gov)
    P1/2, N=36, Terminated, SignalChem Lifesciences Corporation | N=92 --> 36 | Trial completion date: Sep 2028 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: Sep 2026 --> Dec 2025; Lack of efficacy and enrollment challenges
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Keytruda (pembrolizumab) • SLC-391
    1d
    A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001) (clinicaltrials.gov)
    P1, N=168, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jul 2029 --> Jul 2027 | Trial primary completion date: Jul 2029 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab)
    1d
    A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma (clinicaltrials.gov)
    P1, N=322, Active, not recruiting, Sandoz | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab)
    1d
    EVICTION: First-in-Human Study of ICT01 in Patients With Advanced Cancer (clinicaltrials.gov)
    P1/2, N=292, Active, not recruiting, ImCheck Therapeutics | Trial completion date: Dec 2025 --> Oct 2026 | Trial primary completion date: Sep 2025 --> Oct 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition • First-in-human
    |
    Keytruda (pembrolizumab) • ICT01
    2d
    SKYSCRAPER-06: A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=542, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • pemetrexed • tiragolumab (RG6058)
    2d
    Complete remission of recurrent human papillomavirus-associated cervical cancer managed with camrelizumab and nanoparticle albumin-bound paclitaxel as second-line treatment: a case report. (PubMed, Front Immunol)
    The current therapeutic protocols outlined in the National Comprehensive Cancer Network Guidelines 4.2025 edition propose that for second-line or subsequent therapies of cervical carcinoma, prioritized protocols incorporate pembrolizumab administration specifically for patients demonstrating high tumor mutational burden characteristics, positive for programmed cell death ligand 1 expression, or exhibiting microsatellite instability-high/mismatch repair deficiency molecular profiles. Other proposed therapeutic approaches include bevacizumab, paclitaxel, and nanoparticle albumin-bound paclitaxel (nab-paclitaxel)...The patient continues to undergo active clinical surveillance. Our case report illustrates that second-line immunochemotherapy utilizing camrelizumab in combination with nab-paclitaxel exhibits notable efficacy and manageable safety profile.
    Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • AiRuiKa (camrelizumab) • albumin-bound paclitaxel
    2d
    Overcoming resistance in advanced urothelial carcinoma: mechanisms of escape from antibody-drug conjugates and FGFR3 inhibition. (PubMed, Front Oncol)
    Enfortumab vedotin, a Nectin-4 targeting ADC, is now the first line therapy of choice in combination with pembrolizumab. Erdafitinib, a pan FGFR1-4 inhibitor, is approved for patients with susceptible FGFR3 alterations...We propose strategies for overcoming resistance including combination strategies, tumor microenvironment modification, and drug structure modification to maximize efficacy. The progress to date in mUC has been remarkable, but there is still significant work to do in this deadly disease and this review highlights the gap between current available therapeutics and cure that so desperately needs to be closed.
    Review • Journal
    |
    FGFR3 (Fibroblast growth factor receptor 3) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    Keytruda (pembrolizumab) • Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)
    2d
    Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=92, Recruiting, Aminex Therapeutics, Inc.
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • fulvestrant • Truqap (capivasertib) • AMXT 1501
    2d
    Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=130, Recruiting, Sairopa B.V. | N=90 --> 130 | Trial completion date: Dec 2025 --> Jul 2027 | Trial primary completion date: Dec 2025 --> May 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • ADU-1805
    2d
    A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=218, Suspended, Sandoz | N=720 --> 218
    Enrollment change
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin